Citadel Advisors’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.55M | Buy |
50,300
+27,000
| +116% | +$2.94M | ﹤0.01% | 4030 |
|
|
2026
Q1 | $2.15M | Sell |
23,300
-40,500
| -63% | -$4.07M | ﹤0.01% | 5927 |
|
|
2025
Q4 | $6.52M | Sell |
63,800
-31,000
| -33% | -$2.77M | ﹤0.01% | 3875 |
|
|
2025
Q3 | $5.92M | Sell |
94,800
-26,200
| -22% | -$1.43M | ﹤0.01% | 4045 |
|
|
2025
Q2 | $6.3M | Buy |
121,000
+60,900
| +101% | +$2.72M | ﹤0.01% | 3729 |
|
|
2025
Q1 | $2.56M | Sell |
60,100
-25,200
| -30% | -$1.09M | ﹤0.01% | 5057 |
|
|
2024
Q4 | $2.61M | Sell |
85,300
-48,400
| -36% | -$1.36M | ﹤0.01% | 5094 |
|
|
2024
Q3 | $3.07M | Sell |
133,700
-17,500
| -12% | -$495K | ﹤0.01% | 4739 |
|
|
2024
Q2 | $4.37M | Buy |
151,200
+60,400
| +67% | +$1.41M | ﹤0.01% | 3962 |
|
|
2024
Q1 | $1.87M | Buy |
90,800
+50,000
| +123% | +$1.07M | ﹤0.01% | 5657 |
|
|
2023
Q4 | $1.1M | Sell |
40,800
-5,600
| -12% | -$147K | ﹤0.01% | 6476 |
|
|
2023
Q3 | $1.38M | Sell |
46,400
-11,100
| -19% | -$390K | ﹤0.01% | 5939 |
|
|
2023
Q2 | $2.06M | Sell |
57,500
-36,000
| -39% | -$1.03M | ﹤0.01% | 5101 |
|
|
2023
Q1 | $2.19M | Sell |
93,500
-89,500
| -49% | -$2.56M | ﹤0.01% | 5184 |
|
|
2022
Q4 | $4.98M | Sell |
183,000
-38,700
| -17% | -$1.77M | ﹤0.01% | 3870 |
|
|
2022
Q3 | $11.9M | Buy |
221,700
+162,700
| +276% | +$8.35M | ﹤0.01% | 2511 |
|
|
2022
Q2 | $2.38M | Sell |
59,000
-15,000
| -20% | -$743K | ﹤0.01% | 5207 |
|
|
2022
Q1 | $4.9M | Buy |
74,000
+14,700
| +25% | +$1.01M | ﹤0.01% | 4213 |
|
|
2021
Q4 | $5.93M | Buy |
59,300
+36,300
| +158% | +$3.75M | ﹤0.01% | 4004 |
|
|
2021
Q3 | $2.88M | Sell |
23,000
-35,900
| -61% | -$4.27M | ﹤0.01% | 5470 |
|
|
2021
Q2 | $7.32M | Sell |
58,900
-21,200
| -26% | -$2.85M | ﹤0.01% | 3660 |
|
|
2021
Q1 | $12.2M | Buy |
80,100
+21,000
| +36% | +$3.17M | ﹤0.01% | 2684 |
|
|
2020
Q4 | $7.62M | Sell |
59,100
-36,600
| -38% | -$4.21M | ﹤0.01% | 3017 |
|
|
2020
Q3 | $10.7M | Buy |
95,700
+34,900
| +57% | +$3.19M | ﹤0.01% | 2211 |
|
|
2020
Q2 | $4.93M | Buy |
60,800
+8,600
| +16% | +$693K | ﹤0.01% | 3097 |
|
|
2020
Q1 | $3.63M | Buy |
52,200
+7,300
| +16% | +$560K | ﹤0.01% | 3171 |
|
|
2019
Q4 | $3.51M | Sell |
44,900
-15,100
| -25% | -$1.09M | ﹤0.01% | 3568 |
|
|
2019
Q3 | $3.83M | Buy |
60,000
+31,400
| +110% | +$2.77M | ﹤0.01% | 3490 |
|
|
2019
Q2 | $2.47M | Sell |
28,600
-3,300
| -10% | -$252K | ﹤0.01% | 4160 |
|
|
2019
Q1 | $2.45M | Buy |
+31,900
| New | +$1.77M | ﹤0.01% | 4119 |
|
Other funds holding GH
DTC
Citadel Advisors's GH Position: Q2 2026 in Review
Citadel Advisors increased its Guardant Health (GH) stake by 87% in Q2 2026, buying an estimated $73.3M and bringing the position to 1,449,534 shares worth $217M. The position accounts for 0.02% of the portfolio, ranked #518.
Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 29 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Citadel Advisors held 1,449,534 shares of Guardant Health worth $217M as of Q2 2026.
- Citadel Advisors bought 673,593 Guardant Health shares in Q2 2026, an estimated $73.3M.
- Guardant Health made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #518 holding.
- Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 29 quarters since.
- 598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.